



FOR IMMEDIATE RELEASE

**Pulmatrix Announces Participation at
2010 BIO International Convention**

Cambridge, MA, May 3, 2010 - Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced, that its CEO, Robert Connelly, will be participating in a session on successful industry M&A, entitled "Goose with the Golden Egg: A Look Back at Biotech's M&A Success Stories."

This panel is being held on Thurs., May 6 from 8-9:00am in Room S405-A at the McCormick Place convention center.

In the world of biopharma M&A, there have been a few deals over the past few years that stand out as clear cut win-win situations. In these transactions a company is able to command a multiple of value that handsomely rewards their stakeholders while the acquirer is able to leverage the technology to increase its value well beyond the initial investment.

This panel will feature a number of the leaders of these "golden egg" companies who will discuss how they managed their resources to generate enviable returns while successfully integrating their technology into the acquiring companies' R&D platform and corporate culture. The discussion will cover understanding opportunities within the industry, building an IP platform, recruiting talent, managing deals and licensing. Mr. Connelly will discuss his experiences as former CEO of Domantis, which was acquired by GlaxoSmithKline in early 2007 for \$454 million.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offering key networking and partnering opportunities, and provides insights and inspiration on the major trends in the industry today. For more information on BIO 2010 visit <http://convention.bio.org>

About Pulmatrix

Pulmatrix is discovering and developing a new class of host targeted therapies that treat and prevent a broad range of infectious and progressive respiratory diseases by harnessing the airway and lungs own natural biophysical properties and host defense mechanisms. Pulmatrix's innovative technology is pathogen-independent so it has broad potential to treat a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive respiratory diseases such as COPD, asthma, and cystic fibrosis. The Pulmatrix technology is based on the ground-breaking scientific work of renowned Harvard Professor David Edwards and Pulmatrix scientists, and is financed by leading life science investors Polaris Venture Partners, 5AM Ventures, ARCH Venture Partners, and the Novartis Bioventures Fund. For additional information about the Company, please visit <http://www.pulmatrix.com>.

###